An enhanceosome containing the Jun B/Fra-2 heterodimer and the HMG-I(Y) architectural protein controls HPV18 transcription

EMBO Reports

Volumn 1, Issue 5, 2000, Pages 422-427

  Bouallaga, Isabelle ^a   Massicard, Séverine ^a,b   Yaniv, Moshe ^a   Thierry, Françoise ^a  

^a Institut Pasteur   (France)

^b IDM Research Laboratory   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL ACETYLTRANSFERASE; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; E7 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; FOSL2 PROTEIN, HUMAN; GLUTATHIONE TRANSFERASE; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP PROTEIN; HYBRID PROTEIN; ONCOPROTEIN; PROTEIN C JUN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FRA 2;

ARTICLE; BINDING SITE; BIOLOGICAL MODEL; CELL NUCLEUS; CHEMISTRY; DIMERIZATION; DOSE RESPONSE; ENHANCER REGION; GENE DELETION; GENETIC TRANSCRIPTION; GENETICS; HELA CELL; HUMAN; METABOLISM; PLASMID; PROTEIN BINDING;

BINDING SITES; CELL NUCLEUS; CHLORAMPHENICOL O-ACETYLTRANSFERASE; DIMERIZATION; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENHANCER ELEMENTS (GENETICS); FOS-RELATED ANTIGEN-2; GENE DELETION; GLUTATHIONE TRANSFERASE; HELA CELLS; HIGH MOBILITY GROUP PROTEINS; HMGA1A PROTEIN; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; ONCOGENE PROTEINS, VIRAL; PLASMIDS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0034331936     PISSN: 1469221X     EISSN: None     Source Type: Journal    
DOI: 10.1093/embo-reports/kvd091     Document Type: Article

References (10)

1. Abdulkadir, S.A., Casolaro, V., Tai, A.K., Thanos, D. and Ono, S.J. (1998) High mobility group I/Y protein functions as a specific cofactor for Oct-2A: mapping of interaction domains. J. Leukoc. Biol., 64, 681-691.
2. Amirand, C., Viari, A., Ballini, J.P., Rezaei, H., Beaujean, N., Jullien, D., Kas, E. and Debey, P. (1998) Three distinct sub-nuclear populations of HMG-I protein of different properties revealed by co-localization image analysis. J Cell Sci., 111, 3551-3561.
3. Arends, M.J., Donaldson, Y.K., Duvall, E., Wyllie, A.H. and Bird, C.C. (1993) Human papillomavirus type 18 associates with more advanced cervical neoplasia than human papillomavirus type 16. Hum. Pathol., 24, 432-437.
4. Bouallaga, I. and Thierry, F. (1999) Control of Human Papillomavirus type 18 transcription: role in carcinogenesis. Recent Res. Devel. Virol., 1, 369-383.
5. Butz, K. and Hoppe-Seyler, F. (1993) Transcriptional control of human papillomavirus (HPV) oncogene expression: composition of the HPV type 18 upstream regulatory region. J. Virol., 67, 6476-6486.
6. Carey, M. (1998) The enhanceosome and transcriptional synergy. Cell, 92, 5-8.
7. Lallemand, D., Spyrou, G., Yaniv, M. and Pfarr, C.M. (1997) Variations in Jim and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts. Oncogens, 14, 819-830.
8. Thierry, F., Dostatni, N., Arnos, F. and Yaniv, M. (1990) Cooperative activation of transcription by bovine papillomavirus type I E2 can occur over a large distance. Mol. Cell. Biol., 10, 4431-4437.
9. Thierry, F., Spyrou, G., Yaniv, M. and Howley, P.M. (1992) Two API sites binding JunB are essential for HPV18 transcription in keratinocytes. J. Virol., 66, 3740-3748.
10. Yie, J., Merika, M., Munshi, N., Chen, G. and Thanos, D. (1999) The role of HMG I(Y) in the assembly and function of the IFN-β enhanceosome. EMBO J., 18, 3074-3089.